- Home
- CRSP
as of 02-27-2026 3:36pm EST
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
| Founded: | 2013 | Country: | Switzerland |
| Employees: | N/A | City: | ZUG |
| Market Cap: | 4.7B | IPO Year: | 2016 |
| Target Price: | $70.00 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.47 | EPS Growth: | -49.08 |
| 52 Week Low/High: | $30.06 - $78.48 | Next Earning Date: | 05-15-2026 |
| Revenue: | $289,590,000 | Revenue Growth: | 9169.85% |
| Revenue Growth (this year): | 1603.19% | Revenue Growth (next year): | 78.75% |
| P/E Ratio: | -9.53 | Index: | N/A |
| Free Cash Flow: | -345928000.0 | FCF Growth: | N/A |
AI-Powered CRSP Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of CRISPR Therapeutics AG (CRSP)
Chief Executive Officer
Avg Cost/Share
$52.58
Shares
6,967
Total Value
$366,324.86
Owned After
226,106
SEC Form 4
General Counsel and Secretary
Avg Cost/Share
$52.58
Shares
2,112
Total Value
$111,048.96
Owned After
85,115
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$60.23
Shares
60,000
Total Value
$3,613,800.00
Owned After
226,106
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$60.19
Shares
34,972
Total Value
$2,104,964.68
Owned After
6,767
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$51.86
Shares
30,000
Total Value
$1,552,497.83
Owned After
226,106
Chief Financial Officer
Avg Cost/Share
$60.13
Shares
29,700
Total Value
$1,786,635.87
Owned After
6,767
Chief Financial Officer
Avg Cost/Share
$56.11
Shares
10,000
Total Value
$559,548.75
Owned After
6,767
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Kulkarni Samarth | CRSP | Chief Executive Officer | Feb 19, 2026 | Sell | $52.58 | 6,967 | $366,324.86 | 226,106 | |
| KASINGER JAMES R. | CRSP | General Counsel and Secretary | Feb 19, 2026 | Sell | $52.58 | 2,112 | $111,048.96 | 85,115 | |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Jan 22, 2026 | Sell | $60.23 | 60,000 | $3,613,800.00 | 226,106 | |
| Prasad Raju | CRSP | Chief Financial Officer | Jan 22, 2026 | Sell | $60.19 | 34,972 | $2,104,964.68 | 6,767 | |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Jan 20, 2026 | Sell | $51.86 | 30,000 | $1,552,497.83 | 226,106 | |
| Prasad Raju | CRSP | Chief Financial Officer | Jan 6, 2026 | Sell | $60.13 | 29,700 | $1,786,635.87 | 6,767 | |
| Prasad Raju | CRSP | Chief Financial Officer | Dec 22, 2025 | Sell | $56.11 | 10,000 | $559,548.75 | 6,767 |
Compare CRSP vs Leading Stocks
See how CRSP stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CRSP CRISPR Therapeutics AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.